HMPL-306
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 75 patients (estimated)
- Sponsors
- Hutchmed
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, MIDH2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1699
- NCT Identifier
- NCT04764474
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.